Related Experiment Video

Updated: Jul 18, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent

Marcel A M Beijk1, Jan J Piek

  • 1Academic Medical Center, University of Amsterdam, Department of Cardiology, Meibergdreef 9, PO Box 22660, 1105 AZ Amsterdam, The Netherlands. m.a.beijk@amc.uva.nl

Expert Review of Medical Devices
|December 26, 2006
PubMed

Insights

Drug-eluting stents (DES) effectively treat coronary artery disease by reducing restenosis. The XIENCE V everolimus-eluting stent shows promise with improved deliverability and sustained drug elution for better vascular compatibility.

Area of Science:

  • Cardiovascular Medicine
  • Biomaterials Science

Background:

  • Drug-eluting stents (DES) are crucial in percutaneous coronary intervention, reducing restenosis and clinical events.
  • Current approved DES include sirolimus-eluting stents (SES), paclitaxel-eluting stents (PES), and zotarolimus-eluting stents (ZES).

Purpose of the Study:

  • To evaluate the safety and efficacy of the XIENCE V everolimus-eluting coronary stent system.
  • To compare the performance of the everolimus-eluting stent with earlier-generation DES.

Main Methods:

  • The study references findings from SPIRIT I, FUTURE I, and II trials involving the everolimus-eluting stent.
  • Assessment of clinical and angiographic outcomes, deliverability, radiopacity, and vascular compatibility.

Main Results:

  • The everolimus-eluting stent demonstrated safety and tolerability.
  • Favorable clinical and angiographic results were observed.
  • The XIENCE V system offers enhanced deliverability, radiopacity, and sustained drug elution via a durable polymer.

Conclusions:

  • The XIENCE V everolimus-eluting coronary stent system is a safe and effective option for coronary artery disease treatment.
  • It presents potential advantages over previous DES generations, including improved vascular compatibility.

Related Concept Videos

Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...